{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:55:18Z","timestamp":1787874918080,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.chest.2022.05.035","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:09:57Z","timestamp":1654081797000},"page":"1188-1198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung\u00a0Cancer"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-7524","authenticated-orcid":false,"given":"Yuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Sumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Shibaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-739X","authenticated-orcid":false,"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-9138","authenticated-orcid":false,"given":"Yoshihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2022.05.035_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.05.035_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.05.035_bib3","article-title":"Japanese Lung Cancer Society guidelines for stage IV NSCLC with EGFR mutations","volume":"2","author":"Ninomiya","year":"2020","journal-title":"JTO Clin Res Rep"},{"issue":"14","key":"10.1016\/j.chest.2022.05.035_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168465","article-title":"Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer","volume":"11","author":"Fujimoto","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.chest.2022.05.035_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.016","article-title":"Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naive patients with non-squamous non-small cell lung cancer: a multicentre, retrospective cohort study","volume":"150","author":"Fujimoto","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1164\/ajrccm.177.12.1397a","article-title":"Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients","volume":"177","author":"Azuma","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2022.05.035_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.chest.2022.05.035_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.chest.2022.05.035_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.chest.2022.05.035_bib12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with Osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.chest.2022.05.035_bib13","unstructured":"Lorenzi M, Ferro A, Cecere F, et\u00a0al. First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study [published ahead of print August 23, 2021]. Oncologist."},{"key":"10.1016\/j.chest.2022.05.035_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.chest.2022.05.035_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.chest.2022.05.035_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jtho.2018.04.038","article-title":"Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication","volume":"13","author":"Lee","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib18","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jtho.2016.08.144","article-title":"Transient asymptomatic pulmonary opacities occurring during osimertinib treatment","volume":"11","author":"Noonan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9352","key":"10.1016\/j.chest.2022.05.035_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.chest.2022.05.035_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2022.05.035_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMoa1007285","article-title":"Lung volumes and emphysema in smokers with interstitial lung abnormalities","volume":"364","author":"Washko","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2022.05.035_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus","year":"2004","journal-title":"Respiration"},{"issue":"suppl 2","key":"10.1016\/j.chest.2022.05.035_bib23","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","article-title":"Diagnosis and management of drug-associated interstitial lung disease","volume":"91","author":"M\u00fcller","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.chest.2022.05.035_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Invest"},{"key":"10.1016\/j.chest.2022.05.035_bib26","doi-asserted-by":"crossref","first-page":"S1322","DOI":"10.1016\/j.annonc.2021.08.2123","article-title":"LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study","volume":"32","author":"Kenmotsu","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.chest.2022.05.035_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.chest.2022.05.035_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.chest.2022.05.035_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2019.04.028","article-title":"Management strategies for early-onset pulmonary events associated with Brigatinib","volume":"14","author":"Camidge","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib30","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.chest.2022.05.035_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib32","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2022.05.035_bib33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyt049","article-title":"Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two phase III trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.chest.2022.05.035_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201002-0188OC","article-title":"EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium","volume":"183","author":"Harada","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2022.05.035_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.chest.2021.06.035","article-title":"Detection and early referral of patients with interstitial lung abnormalities: an expert survey initiative","volume":"161","author":"Hunninghake","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2022.05.035_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir Invest"},{"issue":"12","key":"10.1016\/j.chest.2022.05.035_bib37","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","article-title":"Development and progression of interstitial lung abnormalities in the Framingham Heart Study","volume":"194","author":"Araki","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.05.035_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejro.2019.03.003","article-title":"Interstitial lung abnormality in stage IV non-small cell lung cancer: a validation study for the association with poor clinical outcome","volume":"6","author":"Araki","year":"2019","journal-title":"Eur J Radiol Open"},{"issue":"6","key":"10.1016\/j.chest.2022.05.035_bib39","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","article-title":"Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib\u2014a cohort study","volume":"15","author":"Johkoh","year":"2014","journal-title":"Clin Lung Cancer"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222010686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222010686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:45:09Z","timestamp":1757925909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222010686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0012369222010686"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.05.035","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung\u00a0Cancer","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}